Therapies with emerging evidence of efficacy: avotermin for the improvement of scarring.
Many patients are dissatisfied with scars on both visible and non-visible body sites and would value any opportunity to improve or minimise scarring following surgery. Approximately 44 million procedures in the US and 42 million procedures in the EU per annum could benefit from scar reduction therapy. A wide range of non-invasive and invasive techniques have been used in an attempt to improve scarring although robust, prospective clinical trials to support the efficacy of these therapies are lacking. Differences in wound healing and scar outcome between early fetal and adult wounds led to interest in the role of the TGFbeta family of cytokines in scar formation and the identification of TGFbeta3 (avotermin) as a potential therapeutic agent for the improvement of scar appearance. Extensive pre-clinical and human Phase I and II clinical trial programmes have confirmed the scar improving efficacy of avotermin which produces macroscopic and histological improvements in scar architecture, with improved restitution of the epidermis and an organisation of dermal extracellular matrix that more closely resembles normal skin. Avotermin is safe and well tolerated and is currently in Phase III of clinical development, with the first study, in patients undergoing scar revision surgery, fully recruited.
Bush
Jim
J
Renovo, Core Technology Facility, 48 Grafton Street, Manchester M13 9XX, UK.
So
Karen
K
Mason
Tracey
T
Occleston
Nick L
NL
O'Kane
Sharon
S
Ferguson
Mark W J
MW
Plast Reconstr Surg. 2006 Sep 15;118(4):909-918
16980850
Plast Reconstr Surg. 2002 Aug;110(2):560-71
12142678
Int J Low Extrem Wounds. 2008 Sep;7(3):160-8
18757391
J Am Coll Surg. 2008 Apr;206(4):719-30
18387479
Drug Discov Today. 2008 Nov;13(21-22):973-81
18824245
Plast Reconstr Surg. 1996 Apr;97(4):854-60
8628785
Lancet. 1992 Jan 25;339(8787):213-4
1346175
J Biol Chem. 2005 Jun 3;280(22):21329-36
15799969
Philos Trans R Soc Lond B Biol Sci. 2004 May 29;359(1445):839-50
15293811
Plast Reconstr Surg. 2009 Jul;124(1):256-265
19568089
Expert Opin Emerg Drugs. 2006 Mar;11(1):39-47
16503825
Wound Repair Regen. 2008 Jan-Feb;16(1):80-6
18086295
J Plast Reconstr Aesthet Surg. 2008;61(1):4-17
17644502
J Biomater Sci Polym Ed. 2008;19(8):1047-63
18644230
Ann Surg. 1995 Aug;222(2):146-54
7639582
Plast Reconstr Surg. 2008 May;121(5):1650-1658
18453989
Plast Reconstr Surg. 2008 Feb;121(2):487-496
18300967
Clin Plast Surg. 2009 Apr;36(2):307-13, viii
19309655
Lancet. 2009 Apr 11;373(9671):1264-74
19362676
Dermatol Surg. 2009 Aug;35(8):1172-80
19250300
Int J Biochem Cell Biol. 1997 Jan;29(1):63-78
9076942
Plast Reconstr Surg. 2008 Oct;122(4):1068-1078
18827639
J Cell Sci. 1995 Mar;108 ( Pt 3):985-1002
7542672